375 results on '"Aamdal, S"'
Search Results
2. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
3. Immunobead-Based Detection and Characterization of Circulating Tumor Cells in Melanoma Patients
4. Acute liver graft rejection after ipilimumab therapy
5. A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
6. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
7. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance
8. HTERT/SURVIVIN MRNA-LOADED DENDRITIC CELL VACCINATION COMBINED WITH EX-VIVO EXPANDED T CELL TRANSFER IN STAGE IV MELANOMA PATIENTS SHOW A LONGER OVERALL SURVIVAL IN PATIENTS WITH SUSTAINED IMMUNE RESPONSES AGAINST HTERT: PH-P065
9. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
10. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755
11. Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours
12. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)
13. A paradigm shift in early drug development: individualizing to more patient benefit
14. Phase II study of E7070 in patients with metastatic melanoma
15. Immunobead-Based Detection and Characterization of Circulating Tumor Cells in Melanoma Patients
16. Experiences with clinical-grade production of mRNA transfected dendritic cells used as cancer vaccines
17. CLINICAL TRIALS OF PEPTIDE BASED VACCINES TARGETING TELOMERASE
18. Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study
19. Fotemustine (F) versus Dacarbazine (DTIC) as first line treatment in disseminated malignant melanoma (MM) with or without brain metastases (BM): A randomized phase III trial
20. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
21. Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
22. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 'CREATE'
23. Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
24. The Usefulness of the Nude Mouse Model for Predicting the Chemosensitivity of Human Tumors. Studies in Malignant Melanoma
25. Telomerase peptide vaccine combined with ipilimumab in metastatic melanoma: Reports from a phase I trial
26. Results from a first in man Phase I/II adjuvant Dendritic Cell Vaccine study in high risk prostate cancer patients following radical surgery
27. UV1 - A peptide-based, therapeutic cancer vaccine targeting the reverse transcriptase subunit of human telomerase (hTERT)
28. Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
29. Late abstracts 186–187
30. Phase II studies of docetaxel in the treatment of various solid tumors
31. Defining the Critical Hurdles in Cancer Immunotherapy
32. Treatment profile of saracatinib (AZD0530) in combination with chemotherapy in patients with advanced ovarian carcinoma
33. Predictive and prognostic value of serum YKL-40 post surgery in patients with stage IIB-III melanoma receiving adjuvant interferon therapy
34. 1154P - Telomerase peptide vaccine combined with ipilimumab in metastatic melanoma: Reports from a phase I trial
35. 21 - Results from a first in man Phase I/II adjuvant Dendritic Cell Vaccine study in high risk prostate cancer patients following radical surgery
36. High-Dose Concurrent Mesna Infusion May Interfere with the Antitumor Activity of Ifosfamide
37. New Tissue-Specific Metastasis Models in Adult Nude Mice
38. Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group
39. Extended TME- and MRI-assisted pathology show high incidence of pt4 after neoadjuvant treatment
40. hTERT/survivin mRNA-loaded dendritic cell vaccination combined with ex-vivo expanded T cell transfer in stage IV melanoma patients show a longer overall survival in patients with sustained immune responses against hTERT
41. 36P - UV1 - A peptide-based, therapeutic cancer vaccine targeting the reverse transcriptase subunit of human telomerase (hTERT)
42. [Gene therapy in cancer]
43. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
44. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
45. Defining the Critical Hurdles in Cancer Immunotherapy
46. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance
47. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
48. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
49. Clinical experiences with therapeutic DC vaccines targeting autologous cancer stem cells in glioblastoma
50. A Paradigm Shift in Early Drug Development: Individualizing to More Patient Benefit
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.